Frontlight ResearchEarly access
Taking people in ItalyPhase 2
Ivabradine given early to children in hospital with heart failure
Tests ivabradine on heart rate in children hospitalized with heart failure from dilated cardiomyopathy.
Key facts
- Who runs it
- Ospedale Pediatrico Bambino Gesu
- Where
- Rome, ItalySee the site
- Registry title
- EArly adminiStration of Ivabradine in CHILDren with heart failure
- Status
- Recruiting
- Phase
- Phase 2
- People taking part
- 9 people, planned
- Started
- 19 Mar 2025
- Expected to end
- 1 Jun 2027
- Type of study
- Interventional
- Record updated
- 2 August 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for children and teenagers with dilated cardiomyopathy (an enlarged, weak heart muscle) who had acute heart failure in the last three months. It tests whether ivabradine lowers the heart rate.
- Age
- From 3 years to under 18 years.
- Sex
- All sexes can join.
- Disease stage
- Dilated cardiomyopathy (heart enlarged more than 2 SD and moving weakly). NYHA/Ross class II or higher. Ejection fraction below 40%. An episode of acute heart failure in the last three months, new or returning.
- Earlier treatment
- People who got an experimental drug in another study within 30 days or 5 half-lives of the study drug cannot join.
- Biomarker or test result
- Weight 25 kg (55 lb) or more. Systolic blood pressure above the 50th percentile for age and height. Heart rate 75 bpm or more at ages 3-5, above 70 bpm at ages 5-18.
Main reasons for not taking part
- Hypertrophic, restrictive or mixed cardiomyopathy, or acute lymphocytic myocarditis shown by heart biopsy
- Serious heart valve disease, sinoatrial block, congenital long QT syndrome or atrial fibrillation
- AST or ALT more than 2.5 times normal, bilirubin above 3mg/dL, creatinine above 2.5 mg/dL (221 µmol/L), or eGFR below 15 mL/min/1.73 m2
- Pregnancy or a positive pregnancy test
- Allergy to the drug, chronic lung disease, or not able to swallow tablets
The registry criteria, word for word
Show all 3 criteriaShow less
Who can take part
- Patients ≥ 3 years of age and under 18 years of age and weight ≥ 25 kg; Dilated cardiomyopathy defined according to the indications of the Cardiomyopathy Task Force (dilation > 2 SD and hypokinesia); NYHA/Ross Classification ≥ II; Ejection fraction < 40%; Patients with episode of acute heart failure (both de novo and relapse) in the last three months; Systolic blood pressure > 50th percentile per age and height; Heart rate: 3-5 years ≥75 bpm; 5-18 years >70 bpm; Signed Informed Consent Form (ICF)/Assent by the subject
Who cannot take part
- Hypertrophic, restrictive or mixed cardiomyopathy; Acute lymphocytic myocarditis diagnosed by endomyocardial biopsy; Significant Valvular Pathology; Sinoatrial block and congenital long QT-syndrome; Atrial fibrillation; Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels > 2.5 times above the normal values, bilirubin > 3mg/dL and creatinine > 2.5 mg/dL. Patients who are pregnant and/or have a positive pregnancy test • Hypersensitivity to the active substance or to any of the excipients. • Participation in a clinical study in which an experimental drug was administered within 30 days or 5 half-lives of the study drug
- Chronic lung disease or other clinical condition that, in the opinion of the investigator, is incompatible with the study.eGFR <15 mL/min/1.73 m2 Inability to swallow tablets
Where in Italy
- Ospedale Pediatrico Bambino GesùRome, ItalyTaking people
About the trial
What the trial wants to find out
To evaluate the response to ivabradine administration in terms of a reduction in heart rate between 20 and 30% from baseline V1 to ivabradine administration on heart rate after 14 days of stable therapy (V3).
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorData and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- Early administration of ivabradine in hospitalized children for heart failure - Easi-child Pilot study
- Plain-language title
- Ivabradine given early to children in hospital with heart failureGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 14 November 2026.
- Record updated
- 2 August 2026